ClinicalTrials.gg
CompletedNCT02914509Updated Oct 11, 2021Results posted

Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT

A Phase 3 interventional study of Travoprost and Placebo Vehicle in Open Angle Glaucoma and Ocular Hypertension, sponsored by Ocular Therapeutix, Inc.. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-11.

Sponsored by Ocular Therapeutix, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
565
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Enrollment
5th of 45
565 · median 135
Started
2016
with 1 other
Phase 3
16 of 46
none open now
Registered
40th of 46
by date
Lead sponsor
1 of 46
Ocular Therapeutix, Inc.

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 5th largest by enrollment of the 45 interventional ones that give a count, is one of 2 that started in 2016, is one of 16 in phase 3, and was the 40th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

The objective of the study is to evaluate evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle glaucoma or ocular hypertension

Read the detailed description

This was a prospective, multicenter, randomized, parallel-arm, double masked, placebo vehicle (PV) controlled study conducted to evaluate the safety and IOP-lowering efficacy of OTX-TP, a sustained release drug product placed in the canaliculus of the eyelid in subjects with open-angle glaucoma or ocular hypertension. A total of up to 550 subjects (1100 eyes) with a clinical diagnosis of open-angle glaucoma or ocular hypertension in both eyes received either OTX-TP or PV to evaluate the safety and efficacy of OTX-TP.

03

Conditions studied

  • Open Angle Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of ocular hypertension with an open angle of Schaffer Grade 3 or greater or open-angle glaucoma without pseudoexfoliation or pigment dispersion or evidence of traumatic angle recession
  • IOP is currently controlled as assessed by the Investigator

Exclusion criteria

Exclusion Criteria:

  • Punctum size smaller than 0.4 mm or greater than 0.9 mm in either eye as measured using a standard punctum gauge
  • A history of an inadequate response or no response to topical prostaglandin
  • Known or suspected allergy and/or to travoprost or any prostaglandin, fluorescein, or to any component of the study products
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
565 participants (actual)

Study arms

  • Experimental
    OTX-TP (sustained release travoprost) Intracanalicular Depot

    OTX-TP (sustained release travoprost) Intracanalicular Depot

    Drug: Travoprost

  • Placebo comparator
    PV (Placebo Vehicle) Intracanalicular Depot

    PV (Placebo Vehicle) Intracanalicular Depot

    Other: Placebo Vehicle

Interventions

06

What researchers measure

Primary outcomes

  1. Mean IOP

    Time frame: Mean IOP at 8AM, 10AM, and 4PM at the 2 Week Visit

  2. Mean IOP

    Time frame: Mean IOP at 8AM, 10AM, and 4PM at the 6 Week Visit

  3. Mean IOP

    Time frame: Mean IOP at 8AM, 10AM, and 4PM at the 12 Week Visit

Other outcomes

  1. Number of Participants With Serious Adverse Events

    Number of Participants with Serious Adverse Events

    Time frame: Through study completion, an average of 23 months

07

Results

Posted Oct 11, 2021

Participant flow

Participant flow — Overall Study
MilestoneOTX-TPPlacebo Vehicle (PV)
Started348217
Completed343211
Not completed56

Outcome measures

PrimaryMean IOP
Time frame:
Mean IOP at 8AM, 10AM, and 4PM at the 2 Week Visit
Reported as:
Mean · mmHg
Mean IOP
mmHgOTX-TP (Sustained Release Travoprost) Intracanalicular DepotPlacebo Vehicle (PV)
8AM21 ± 0.222.9 ± 0.2
10AM20.2 ± 0.221.9 ± 0.2
4PM19.5 ± 0.221.5 ± 0.2
PrimaryMean IOP
Time frame:
Mean IOP at 8AM, 10AM, and 4PM at the 6 Week Visit
Reported as:
Mean · mmHg
Mean IOP
mmHgOTX-TP (Sustained Release Travoprost) Intracanalicular DepotPlacebo Vehicle (PV)
8AM21.9 ± 0.226.9 ± 0.3
10AM25.1 ± 0.225 ± 0.2
4PM24.8 ± 0.224.6 ± 0.2
PrimaryMean IOP
Time frame:
Mean IOP at 8AM, 10AM, and 4PM at the 12 Week Visit
Reported as:
Mean · mmHg
Mean IOP
mmHgOTX-TP (Sustained Release Travoprost) Intracanalicular DepotPlacebo Vehicle (PV)
8AM22.8 ± 0.223.2 ± 0.3
10AM21.7 ± 0.222.5 ± 0.2
4PM21.4 ± 0.222.1 ± 0.2
Other pre-specifiedNumber of Participants With Serious Adverse Events

Number of Participants with Serious Adverse Events

Time frame:
Through study completion, an average of 23 months
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events
ParticipantsOTX-TP (Sustained Release Travoprost) Intracanalicular DepotPlacebo Vehicle (PV)
Number of Participants With Serious Adverse Events76

Adverse events

Collected over through study duration, an average of 23 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OTX-TP (Sustained Release Travoprost) Intracanalicular Depot1/348 (0.3%)7/348 (2%)132/348 (37.9%)
Placebo Vehicle (PV)0/217 (0%)6/217 (2.8%)65/217 (30%)
Most frequent serious events
Most frequent serious events
EventOTX-TP (Sustained Release Travoprost) Intracanalicular DepotPlacebo Vehicle (PV)
Serious Adverse EventInfections and infestations1/3482/217
Serious Adverse EventNervous system disorders2/3480/217
Serious Adverse EventCardiac disorders1/3481/217
Serious Adverse EventRespiratory, thoracic and mediastinal disorders0/3481/217
Serious Adverse EventsEar and labyrinth disorders0/3481/217
Serious Adverse EventInjury, poisoning and procedural complications0/3481/217
Serious Adverse EventNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3480/217
Serious Adverse EventVascular disorders1/3480/217
Serious Adverse EventSkin and subcutaneous tissue disorders1/3480/217
Most frequent other events
Most frequent other events
EventOTX-TP (Sustained Release Travoprost) Intracanalicular DepotPlacebo Vehicle (PV)
Adverse EventGeneral disorders132/34865/217

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)OTX-TP (Sustained Release Travoprost) Intracanalicular DepotPlacebo Vehicle (PV)Total
<=18 years000
Between 18 and 65 years16091251
>=65 years188126314
Age, Continuous
Age, Continuous(years)OTX-TP (Sustained Release Travoprost) Intracanalicular DepotPlacebo Vehicle (PV)Total
Mean65 ± 1165 ± 1165 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)OTX-TP (Sustained Release Travoprost) Intracanalicular DepotPlacebo Vehicle (PV)Total
Female185135320
Male16382245
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)OTX-TP (Sustained Release Travoprost) Intracanalicular DepotPlacebo Vehicle (PV)Total
Caucasian247159406
African American8448132
Other171027
Region of Enrollment
Region of Enrollment(participants)OTX-TP (Sustained Release Travoprost) Intracanalicular DepotPlacebo Vehicle (PV)Total
United States348217565
08

Study locations

10 sites
  • Artesia, California, United States
  • Colorado Springs, Colorado, United States
  • Lakeland, Florida, United States
  • Morrow, Georgia, United States
  • Shawnee Mission, Kansas, United States
  • Des Peres, Missouri, United States
  • Rochester, New York, United States
  • Raleigh, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Austin, Texas, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Mar 2019, 28 months.

Results were first posted in Oct 2021, 2 years 6 months after primary completion.

Of 47 industry-sponsored phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's 28 months is close to that.

Counting every sponsor, half of 49 studies reached it within 26 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2016
First posted
Sep 26, 2016
StartActual
Nov 7, 2016
Primary completionActual
Mar 30, 2019
CompletionActual
Mar 30, 2019
Results first posted
Oct 11, 2021
Last update
Oct 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02914509
Responsible party
Sponsor
First posted
Sep 26, 2016
Start date
Nov 7, 2016
Primary completion
Mar 30, 2019
Completion
Mar 30, 2019
Results posted
Oct 11, 2021
Last update
Oct 11, 2021
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion